A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled, Active-Comparator, Parallel-Group Study to Investigate the Effect of GDC-0449 on the QT/QTc Interval in Healthy Female Subjects.

Trial Profile

A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled, Active-Comparator, Parallel-Group Study to Investigate the Effect of GDC-0449 on the QT/QTc Interval in Healthy Female Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Feb 2017

At a glance

  • Drugs Vismodegib (Primary) ; Moxifloxacin
  • Indications Acute exacerbations of chronic bronchitis; Acute sinusitis; Bacterial infections; Basal cell cancer; Basal cell nevus syndrome; Breast cancer; Colorectal cancer; Community-acquired pneumonia; Gastric cancer; Glioblastoma; Intra-abdominal infections; Medulloblastoma; Ovarian cancer; Pelvic inflammatory disorders; Respiratory tract infections; Skin and soft tissue infections; Tuberculosis
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Apr 2012 Results presented at the 113th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 18 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Nov 2010 Actual initiation date (Mar 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top